Literature DB >> 32016785

Oral Pseudomyogenic Hemangioendothelioma: Case Report and Review of the Literature.

Austin J Shackelford1, Carleigh R Canterbury1, Michael A Perrino2, Joseph Wang3, Elizabeth M Philipone1, Scott M Peters4.   

Abstract

Pseduomyogenic hemangioendothelioma (PMH) is a vascular neoplasm of intermediate biological potential first described by Hornick and Fletcher (Am J Surg Pathol 35:190-201, 2011). Despite its initial categorization as a malignant entity, PMH often demonstrates an indolent behavior profile, and thus was classified as a rarely metastasizing endothelial neoplasm in the 2013 WHO Classification of Tumors of Soft Tissue and Bone. It is a tumor primarily of skin and soft tissue, with most reported cases involving the trunk or extremities. To date, only one case of PMH involving the oral cavity has been reported. Herein, we present a case of PMH involving the mandibular gingiva and vestibule of a 33-year-old female and discuss the salient features of this entity.

Entities:  

Keywords:  Foreign body; Hemangioendothelioma; Oral; Pseduomyogenic; Vascular tumor

Year:  2020        PMID: 32016785      PMCID: PMC7669923          DOI: 10.1007/s12105-020-01137-z

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  16 in total

1.  Epithelioid sarcoma-like hemangioendothelioma.

Authors:  Steven D Billings; Andrew L Folpe; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2003-01       Impact factor: 6.394

2.  CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma.

Authors:  Ryo Shibuya; Atsuji Matsuyama; Eisuke Shiba; Hiroshi Harada; Kei Yabuki; Masanori Hisaoka
Journal:  Histopathology       Date:  2015-05-22       Impact factor: 5.087

3.  Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas.

Authors:  M Miettinen; M Sarlomo-Rikala; L H Sobin; J Lasota
Journal:  Am J Surg Pathol       Date:  2000-02       Impact factor: 6.394

4.  FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma.

Authors:  Yin P Hung; Christopher D M Fletcher; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2017-05       Impact factor: 6.394

5.  Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior.

Authors:  Jason L Hornick; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2011-02       Impact factor: 6.394

6.  Translocation t(7;19)(q22;q13)−a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma?

Authors:  Domenico Trombetta; Linda Magnusson; Fredrik Vult von Steyern; Jason L Hornick; Christopher D M Fletcher; Fredrik Mertens
Journal:  Cancer Genet       Date:  2011-04

7.  Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues.

Authors:  Marc P Pusztaszeri; Walter Seelentag; Fred T Bosman
Journal:  J Histochem Cytochem       Date:  2005-10-18       Impact factor: 2.479

8.  A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma.

Authors:  Charles Walther; Johnbosco Tayebwa; Henrik Lilljebjörn; Linda Magnusson; Jenny Nilsson; Fredrik Vult von Steyern; Ingrid Øra; Henryk A Domanski; Thoas Fioretos; Karolin H Nord; Christopher D M Fletcher; Fredrik Mertens
Journal:  J Pathol       Date:  2014-01-29       Impact factor: 7.996

Review 9.  Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone.

Authors:  Leona A Doyle
Journal:  Cancer       Date:  2014-03-19       Impact factor: 6.860

Review 10.  A rare case of pseudomyogenic hemangioendothelioma (PHE)/epithelioid sarcoma-like hemangioendothelioma (ES-H) of the breast first misdiagnosed as metaplastic carcinoma by FNAB and review of the literature.

Authors:  Yan Ge; Xingtao Lin; Fen Zhang; Fangping Xu; Luqiao Luo; Weiye Huang; Zhihua Liu; Yanhui Liu; Zhi Li
Journal:  Diagn Pathol       Date:  2019-07-17       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.